Key result
AI-powered wearables enable continuous AF detection but complicate thresholds for initiating oral anticoagulation.
Why the study?
Consumer adoption of wearable AF screening devices has increased detection of subclinical AF, creating uncertainty regarding the appropriate threshold for initiating oral anticoagulation.
Do wearable devices integrating multimodal sensors improve the screening, monitoring, and management of atrial fibrillation compared to traditional episodic screening?
Do wearable devices integrating multimodal sensors improve the screening, monitoring, and management of atrial fibrillation compared to traditional episodic screening?
Wearable devices offer a promising closed-loop digital health system for continuous AF screening and management, though successful clinical translation requires standardized algorithms, validated hardware accuracy, and strategies to manage subclinical AF.
May improve real-world AF detection; leaves open need for outcome trials before changing screening practice.
Atrial fibrillation (AF) remains the most prevalent cardiac arrhythmia worldwide, contributing substantially to the risk of ischemic stroke and heart failure. Brief monitoring windows inherently limit traditional episodic screening strategies and frequently fail to detect paroxysmal or asymptomatic occurrences. Wearable devices integrating multimodal sensors-such as photoplethysmography (PPG) and single-lead electrocardiography (ECG)-with artificial intelligence now enable continuous, real-world AF screening. However, the widespread consumer adoption of these technologies has precipitated a novel clinical dilemma. A marked increase in the detection of subclinical atrial fibrillation (SCAF) introduces considerable uncertainty regarding the appropriate threshold for initiating oral anticoagulation. In this review, we evaluate the underlying technical principles of wearable sensors and examine their integration into clinical practice across community screening, postoperative monitoring, and long-term patient management. We critically analyze emerging clinical challenges-focusing on the detection-vs.-intervention paradox emphasized by recent landmark outcome trials-and propose actionable strategies for future implementation. Successful clinical translation will require standardized computational algorithms, validated hardware accuracy, semantic electronic health record (EHR) interoperability, and the continuous quantification of AF burden to tailor personalized antithrombotic therapy.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted a review in Atrial fibrillation. Wearable devices was evaluated. Wearable devices integrating multimodal sensors and artificial intelligence enable continuous atrial fibrillation screening, but their widespread use introduces clinical challenges regarding the appropriate threshold for initiating oral anticoagulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: